Twotobiotech

TwotoBioTech is a privately held biotech company established in 2008, and engaged in developing novel biological molecules. The company's researchers have identified a novel human peptide hormone (called P3) which is expressed in activated immune cells belonging to human innate immune response. TwotoBioTech has subsequently developed a platform technology with several specific mAbs against P3 in order to treat autoimmune diseases. In-vivo studies show that the antibody is highly efficient for treatment of diabetes type 1 and type 2. The company is developing another novel human peptide hormone APC1 for treatment of diabetes type 2 which shows high efficiency in treatment of diabetes type 2 mice in two diabetes type 2 models. The company has also isolated a novel human cardiac peptide which can strongly regulate glucose metabolism.